Prioritizing strategies for comprehensive liver cancer control in Asia: A conjoint analysis

BMC Health Services Research

Volumn 12, Issue 1, 2012, Pages

  Bridges, John F P ^a   Dong, Liming ^a   Gallego, Gisselle ^a   Blauvelt, Barri M ^b   Joy, Susan M ^a   Pawlik, Timothy M ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Conjoint analysis; Discrete choice experiment; Hepatocellular carcinoma (HCC); Liver cancer; Prioritization; Public policy; Strategies

Indexed keywords

ARTICLE; CHINA; CROSS-SECTIONAL STUDY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER TUMOR; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; SOUTH KOREA; TAIWAN;

CARCINOMA, HEPATOCELLULAR; CHINA; CROSS-SECTIONAL STUDIES; HEALTH PLANNING; HEALTH POLICY; HEALTH PRIORITIES; HUMANS; JAPAN; LIVER NEOPLASMS; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; REPUBLIC OF KOREA; TAIWAN;

EID: 84867896284     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-12-376     Document Type: Article

References (69)

1. Epidemiology of liver cancer: an overview. Srivatanakul P, Sriplung H, Deerasamee S, Asian Pac J Cancer Prev 2004 5 118 125 15244512
2. Hepatocellular carcinoma: a global view. Yang JD, Roberts LR, Nat Rev Gastroenterol Hepatol 2010 7 448 458 10.1038/nrgastro.2010.100 20628345
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 International Agency for Research on Cancer, Lyon 2010 http://globocan.iarc.fr
4. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Froman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
5. World Hepatitis Alliance, Viral hepatitis: global policy 2010 http://worldhepatitisalliance.org/Policy/2010PolicyReport.aspx
6. Practical difficulties in the management of hepatitis B in the Asia-pacific region. Mohamed R, Desmond P, Suh DJ, Amarapurkar D, Gane E, Guangbi Y, Hou JL, Jafri W, Lai CL, Lee CH, Lee SD, Lim SG, Guan R, Phiet PH, Piratvisuth T, Sollano J, Wu JC, J Gastroenterol Hepatol 2004 19 958 969 10.1111/j.1440-1746.2004.03420.x 15304110 (Pubitemid 39237427)
7. Korean Ministry of Health and Welfare, Blood management policy 2012 http://english.mohw.go.kr/front-eng/jc/sjc0102mn.jsp?PAR-MENU-ID= 100302&MENU-ID=10030203
8. National cancer control programs in Korea. J Korean Med Sci 2007 22 3 S4 18077892
9. Liver Cancer and its Prevention. Tsukuma H, Tanaka H, Ajiki W, Oshima A, Asian Pac J Cancer Prev 2005 6 244 250 16235981
10. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Yoshizawa H, Intervirology 2006 49 7 17 10.1159/000087257 16166783 (Pubitemid 41318170)
11. A study of the awareness of chronic liver diseases among Korean adults. Jun DW, Cho YK, Sohn JH, Lee CH, Kim SH, Eun JR, Korean J Hepatol 2011 17 99 105 10.3350/kjhep.2011.17.2.99 21757980
12. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian oncology summit 2009. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, Khin MW, Koo WH, Lancet Oncol 2009 10 1111 1118 10.1016/S1470-2045(09)70241-4 19880065
13. WHO, National cancer control programmes: policies and managerial guidelines World Health Organization, Geneva 2nd edition 2002
14. Guidelines for international breast health and cancer control-implementation. Anderson BO, Distelhorst SR, Cancer 2008 113 Suppl 8 2215 2216 18837029
15. World Health Organization, Department of Reproductive Health and Research and Department of Chronic Diseases and Health Promotion, Comprehensive cervical cancer control: a guide to essential practice World Health Organization, Geneva 2006
16. Public policy action and CCC implementation: benefits and hurdles. Steger C, Daniel K, Gurian GL, Petherick JT, Stockmyer C, David AM, Miller SE, Cancer Causes Control 2010 21 2041 2048 10.1007/s10552-010-9668-5 21086034
17. Needs for hepatocellular carcinoma (HCC) control policy in the Asia-pacific region. Bridges J, Joy S, Gallego G, Kudo M, Han K-H, Ye S-L, Cheng A-L, Blauvelt B, Asian Pac J Cancer Prev 2011 12 2585 2591 22320959
18. Priorities for hepatocellular carcinoma (HCC) control: a comparison of policy needs in five European countries. Bridges J, Joy S, Gallego G, Blauvelt B, Geschwind JF, Pawlik T, J Comp Pol Anal 2012 14 352 368
19. Improving the use of research evidence in guideline development: 2. priority setting. Oxman AD, Schünemann HJ, Fretheim A, Health Res Policy Syst 2006 4 14 20 10.1186/1478-4505-4-14 17134481 (Pubitemid 46017444)
20. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan society of hepatology (JSH) 2010 updated version. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M, Dig Dis 2011 29 339 364 10.1159/000327577 21829027
21. Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists. Sharma P, Saini SD, Kuhn LB, Rubenstein JH, Pardi DS, Marrero JA, Schoenfeld PS, Dig Dis Sci 2011 56 569 577 10.1007/s10620-010-1453-5 20978844
22. A study of the awareness of chronic liver diseases among Korean adults. Jun DW, Cho YK, Sohn JH, Lee CH, Kim SH, Eun JR, Korean Journal Hepatol 2011 17 99 105 10.3350/kjhep.2011.17.2.99
23. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P, Lancet Oncol 2009 10 35 43 10.1016/S1470-2045(08)70284-5 19058754
24. Liver transplantation for hepatocellular carcinoma: expanding frontiers and building bridges. Masuoka HC, Rosen CB, Clin Liver Dis 2011 15 385 393 10.1016/j.cld.2011.03.005 21689620
25. Hepatitis B virus-related hepatocellular carcinoma: primary, secondary, and tertiary prevention. Giacomin A, Cazzagon N, Sergio A, Vanin V, Farinati F, Eur J Cancer Prev 2011 20 381 388 10.1097/CEJ.0b013e328346399b 21540746
26. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, Porter G, Kachura JR, Rasuli P, Gill S, Ghali P, Chaudhury P, Siddiqui J, Valenti D, Weiss A, Wong R, Curr Oncol 2011 18 228 240 21980250
27. Evaluating priority setting success in healthcare: a pilot study. Sibbald SL, Gibson JL, Singer PA, Upshur R, Martin DK, BMC Health Serv Res 2010 10 131 144 10.1186/1472-6963-10-131 20482843
28. Priority setting in health-a political economy perspective. Goddard M, Hauck K, Smith PC, Health Econ Policy Law 2006 1 79 90 18634704
29. Disease control priorities in developing countries World Bank, Washington, DC, Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, 2006 http://files.dcp2.org/pdf/DCP/DCPFM.pdf
30. What can economics add to health technology assessment? please not just another cost-effectiveness analysis! Bridges JF, Expert Rev Pharmacoecon Outcomes Res 2006 6 19 24 10.1586/14737167.6.1.19 20528533
31. Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Bridges JF, Appl Health Econ Health Policy 2003 2 213 224 15119540
32. Longevity bias in cost-effectiveness analysis. Liu L, Rettenmaier AJ, Saving TR, Health Econ 2008 17 523 534 10.1002/hec.1309 17990284 (Pubitemid 351517410)
33. Common methodological flaws in economic evaluations. Drummond M, Sculpher M, Med Care 2005 43 suppl 7 5 14 16056003
34. Evidence-based priority-setting: what do the decision-makers think? Mitton C, Patten S, J Health Serv Res Policy 2004 9 146 152 10.1258/ 1355819041403240 15272972 (Pubitemid 38954935)
35. An experimental application of the DELPHI method to the use of experts. Dalkey N, Helmer O, Manag Sci 1963 9 458 467 10.1287/mnsc.9.3.458
36. A checklist for health research priority setting: nine common themes of good practice. Viergever RF, Olifson S, Ghaffar A, Terry RF, Health Res Policy Syst 2010 8 36 44 21159163
37. Deliberations about deliberative methods: issues in the design and evaluation of public participation processes. Abelson J, Forest P-G, Eyles J, Smith P, Martin M, Gauvin F-P, Soc Sci Med 2003 57 239 251 10.1016/S0277- 9536(02)00343-X 12765705 (Pubitemid 36582667)
38. Qualitative methods for assessing health care. Fitzpatrick R, Boulton M, Qual Health Care 1994 3 107 113 10.1136/qshc.3.2.107 10137583
39. Focus groups in psychological assessment: enhancing content validity by consulting members of the target population. Vogt DS, Psychol Assess 2004 16 3 231 243 15456379 (Pubitemid 39244708)
40. Validity and qualitative research: an oxymoron? Onwuegbuzie AJ, Leech NL, Qual Quant 2007 41 233 249 10.1007/s11135-006-9000-3
41. The citizens' jury model of public participation: a critical evaluation. Armour A, Fairness and competence in citizen participation Kluwer Academic Publishers, Dordrecht, Renn O, Webler T, Wiedemann P, 1995 175 185 Technology, risk, and society: an international series in risk analysis, vol 10
42. Multi-criteria clinical decision support: a primer on the use of multiple criteria decision making methods to promote evidence-based, patient-centered healthcare. Dolan JG, Patient 2010 3 229 248 10.2165/11539470-000000000-00000 21394218
43. Eliciting public preferences for healthcare: a systematic review of techniques. Ryan M, Scott DA, Reeves C, Bate A, van Teijlingen ER, Russell EM, Napper M, Robb CM, Health Technol Assess 2001 5 1 186 12387733
44. A test of concordance between patient and psychiatrist valuations of multiple treatment goals for schizophrenia. Bridges JF, Slawik L, Schmeding A, Reimer J, Naber D, Kuhnigk O, Health Expect 2011 Epub ahead of print 10.1111/j.1369-7625.2011.00704.x
45. Condom avoidance and determinants of demand for male circumcision in Johannesburg, South Africa. Bridges JF, Selck FW, Gray GE, McIntyre JA, Martinson NA, Health Policy Plan 2011 26 298 306 10.1093/heapol/czq064 20961943
46. Engaging families in the choice of social marketing strategies for male circumcision services in Johannesburg, south Africa. Bridges JFP, Searle SC, Selck FW, Martinson NA, Soc Market Q 2010 16 60 76 10.1080/15245004.2010.500443
47. Best-worst scaling: what it can do for health care research and how to do it. Flynn TN, Louviere JJ, Peters TJ, Coast J, J Health Econ 2007 26 171 189 10.1016/j.jhealeco.2006.04.002 16707175 (Pubitemid 44908719)
48. McFadden D, In Frontiers in Econometrics, Conditional logit analysis of qualitative choice behavior Edited by Zarembka P, New York: Academic Press 1974 105 142
49. A law of comparative judgment. Thurstone LL, Psychol Rev 1927 34 273 286
50. Determining the appropriate response to evidence of public concern: the case of food safety. Finn A, Louviere J, Journal of Public Policy & Marketing 1992 11 12 25 20169798
51. Street D, Street AP, Combinatorics of experimental design Clarendon Press, Oxford 1987
52. Using conjoint analysis and choice experiments to estimate QALY values: issues to consider. Flynn TN, PharmacoEconomics 2010 28 711 722 10.2165/11535660-000000000-00000 20568837
53. WHO, Cancer control: knowledge into action. WHO guide for effective programmes World Health Organization, Geneva 2006
54. Identifying and prioritizing strategies for comprehensive liver cancer control in Asia. Bridges JF, Gallego G, Kudo M, Okita K, Han KH, Ye SL, Blauvelt BM, BMC Health Serv Res 2011 11 298 309 10.1186/1472-6963-11-298 22047535
55. Conjoint analysis in consumer research: issues and outlook. Green PE, Srinivasan V, J Consum Res 1978 5 103 123 10.1086/208721
56. Conducting discrete choice experiments to inform healthcare decision making: a user's guide. Lancsar E, Louviere J, PharmacoEconomics 2008 26 661 677 10.2165/00019053-200826080-00004 18620460 (Pubitemid 351989058)
57. Using conjoint analysis to elicit preferences for health care. Ryan M, Farrar S, BMJ 2000 320 1530 1533 10.1136/bmj.320.7248.1530 10834905 (Pubitemid 30330316)
58. Discrete choice experiments to measure consumer preferences for health and healthcare. Viney R, Lancsar E, Louviere J, Expert Rev Pharmacoecon Outcomes Res 2002 2 319 326 10.1586/14737167.2.4.319 19807438
59. Conjoint analysis applications in health-a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, Johnson FR, Mauskopf J, Value Health 2011 14 403 413 10.1016/j.jval.2010.11.013 21669364
60. Estimating patients' preferences for medical devices: does the number of profiles in choice experiments matter? Bridges JFP, Buttorff C, Groothuis-Oudshoorn K, NBER Working Paper 2011 17482
61. Conjoint analysis applications in health-how are studies being designed and reported? An update on current practice in the published literature between 2005 and 2008. Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, Johnson FR, Patient 2010 3 249 256 10.2165/11539650-000000000-00000 22273432
62. Kuhfeld WS, Orthogonal arrays SAS Knowledge Base Papers TS-723. Raleigh, SAS Institute Inc 2012 http://support.sas.com/techsup/technote/ts723.html
63. An algorithm for restricted least squares regression. Dykstra RL, J Am Statist Assoc 1983 78 837 842 10.1080/01621459.1983.10477029
64. Hauser JR, Rao VR, In Advances in Marketing Research, Conjoint analysis, related modeling, and applications Progress and Prospects. Edited by Wind Y, Green PE, New York: Springer 2004 141 168
65. Angrist JD, Pischke J-S, Mostly harmless econometrics: an Empiricist's companion Princeton University Press, Princeton 2009
66. Market potential for fine furniture manufactured from low-grade hardwood: evidence from a conjoint analysis in the northeastern united states. Wang Q, Shi G, Chan-Halbrendt C, Forest Prod J 2004 54 19 25
67. Hepatocellular carcinoma in Taiwan. Chen DS, Hepatol Res 2007 37 101 S105 10.1111/j.1872-034X.2007.00170.x 17877468
68. Ethical and legislative perspectives on liver transplantation in the People's republic of china. Huang J, Liver Transpl 2007 13 193 196 10.1002/lt.21081 17256779 (Pubitemid 46351643)
69. Liver transplantation in china: problems and their solutions. Wu J, Zheng SS, Hepatobiliary Pancreat Dis Int 2004 3 170 174 15138103 (Pubitemid 38660143)